PEG & ADCs
- ROR1 ADCs in Clinical Trials: MK-2140, NBE-002 & CS5001
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Summary of ADC Targets For Solid Tumors & Hematological Tumors
- Antibody-Drug Conjugates With Dual Payloads Against Heterogeneous Tumors
- Design Elements And Design Criteria For ADC Drugs
- Overview of ADC-Based Combination Therapies
- Advances in TROP-2 Directed ADCs
- Development of PD-L1 Antibody Drug Conjugates (ADC)
- Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
- Nectin-4: New Antibody-Drug Conjugate (ADC) Target